What Ethan Zohn's Story Can Help Us Understand About Hodgkin Lymphoma

What Zohn has said in public

Ethan Zohn won Survivor: Africa. Years later he became known for something else: talking openly about lymphoma while he was still in the middle of it.

ABC News reported in November 2011 that Zohn, then 37, had told People magazine his Hodgkin lymphoma had come back. He said he had been in remission for almost two years before that. He also described where it had returned: "It's localized in my lung area."

In February 2012, TODAY reported that Zohn had a stem cell transplant to treat that recurrence, and that his brother was the donor.

That is the public record, and this page stays inside it. Nothing here describes his stage, his drugs, or his health now.

A cancer named after one strange cell

Lymphoma is cancer of the lymph system — the network of vessels, nodes, and organs that moves immune cells around the body. The two broad families are Hodgkin lymphoma and non-Hodgkin lymphoma, and they are not variations on a theme. They are treated differently and they behave differently.

What sets Hodgkin lymphoma apart is a cell. Under a microscope, a pathologist looks for Reed-Sternberg cells: large, odd-looking cells with more than one nucleus. Almost all of the tissue in a swollen Hodgkin node is ordinary immune cells reacting to those few strange ones.

That cell also gives treatment a handle. Reed-Sternberg cells carry a surface protein called CD30, which NCI's clinical summary lists as part of the classic Hodgkin marker pattern (CD15+, CD20−, CD30+, CD45−). A drug called brentuximab vedotin uses CD30 as an address: it is an antibody carrying a chemotherapy payload, delivered mostly where the target is.

Staging, and the letter after the number

Hodgkin lymphoma is staged I through IV by how many groups of lymph nodes are involved and whether the disease sits on one or both sides of the diaphragm.

A letter follows the number. B means the person has what clinicians call B symptoms. NCI defines these precisely: unexplained weight loss of more than 10% of body weight in the six months before diagnosis, unexplained fever above 38°C, or drenching, repeated night sweats. Fevers and weight loss carry the most weight; night sweats alone do not worsen the outlook.

Staging is not just bookkeeping. NCI notes that the strongest predictor of whether treatment will fail is a PET-CT scan taken after two cycles of chemotherapy — the PET2 scan. Teams use it to add or subtract treatment early, rather than waiting to the end.

When to get checked

Hodgkin lymphoma has no screening test, so it is found by someone noticing something. Worth a same-week appointment:

• A swollen lymph node in the neck, armpit, or groin that has lasted more than three or four weeks, is painless, and is not shrinking.
• Fevers with no infection behind them, especially if they keep returning.
• Night sweats heavy enough that you change the sheets or your clothes.
• Losing more than a tenth of your body weight in six months without trying.
• A cough, breathlessness, or a full feeling in the chest that will not settle.

Most enlarged nodes are infection. The point is the ones that do not go away. Our overview of lymphoma explains what happens after a node is removed and looked at.

What treatment involves

First treatment for Hodgkin lymphoma is usually a combination of chemotherapy drugs, sometimes with radiation aimed at the nodes that were involved. The number of cycles depends on stage and on the PET2 result. Checkpoint inhibitors and brentuximab vedotin have moved into earlier lines of treatment over the past decade.

If the disease comes back, the standard route is different: stronger chemotherapy, then a stem cell transplant.

That word covers two very different procedures. In an autologous transplant, a person's own blood stem cells are collected first, then given back after high-dose chemotherapy, to rebuild marrow that the chemotherapy has wiped out. In an allogeneic transplant, the cells come from a donor — often a sibling — and the donor immune system itself becomes part of the treatment. That second kind carries the extra risk of graft-versus-host disease, where donor cells attack the recipient's tissues. Our guide to stem cell transplant walks through the timeline.

What the numbers describe

The American Cancer Society projects about 8,920 new cases of Hodgkin lymphoma in the United States in 2026, and about 1,100 deaths, and SEER, the federal cancer surveillance program, reprints them. It is one of the rarer cancers, and one of the youngest: SEER's own records put the median age at diagnosis at 38.

Five-year relative survival is 89.3% overall. By stage at diagnosis it runs 92.7% for stage I, 95.4% for stage II, 87.7% for stage III, and 82.8% for stage IV. Stage IV Hodgkin lymphoma is not the sentence that stage IV implies in most other cancers.

These are group averages drawn from people diagnosed years ago. They do not predict anything for one person.

What this does not mean

A recurrence is not the same event as a first diagnosis, and it is not the end of treatment options — but it is also not something anyone can promise about. Zohn's course was his.

"Hodgkin lymphoma is curable" is a true sentence about a population and a useless one at the bedside. What matters for an individual is subtype, stage, B symptoms, how the PET2 scan looks, and what the team can offer.

And survivorship is not a finish line. Treatment that works this well leaves people with decades of life and, sometimes, late effects on the heart, lungs, thyroid, or fertility that need watching. Survivorship care is a real part of the plan, not an afterthought.

Sources

• ABC News: 'Survivor' Star Ethan Zohn Says Cancer Returns
• TODAY (NBC News): 'Survivor's' Ethan Zohn gets a stem-cell transplant
• NCI PDQ: Hodgkin Lymphoma Treatment (Health Professional Version)
• NCI SEER Cancer Stat Facts: Hodgkin Lymphoma

How this article was prepared

An AI-assisted editorial system helped prepare this page. No named medical reviewer has reviewed it unless one is listed.

Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.

See an error, old source, or unclear wording? Tell us.